$434 Million Monkeypox Vaccine Contract with Canada
Denmark-based Bavarian Nordic A/S announced today a revised contract with the Public Health Agency of Canada to supply doses of the IMVAMUNE® (Jynneos®) smallpox vaccine at approximately US $234 million in addition to the US $180 million in contract options.
This extends the current US $56 million contract awarded in June 2022 to a total value of up to the US $470 million.
Furthermore, a new multi-year contract has been signed with Canada’s Department of National Defence at a value of US $2 million, in addition to the US $18 million in contract options.
Through these agreements, the majority of the firm order supply will be delivered in 2023, with the option to procure additional doses annually until 2032.
Developed in collaboration with the U.S. government, the two-dose Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S., and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine.
The U.S. FDA issued its approval for the Jynneos vaccine in 2019.
Paul Chaplin, President & CEO of Bavarian Nordic, said in a media statement on September 20, 2022, “With foresight and prioritization, Canada has shown the way to building a robust preparedness for its population."
As of September 19, 2022, the U.S. CDC has reported 23,893 monkeypox / orthopoxvirus cases since May 2022.
And worldwide, data sources indicate over 66,400 cases and 23 related fatalities have been reported during the monkeypox outbreak this year.
Additional monkeypox outbreak news is posted at MonkeypoxToday.